NGR013: Phase I and Pharmacodynamic Study of NGR-hTNF Administered at High Doses in Patients With Advanced or Metastatic Solid Tumour.

Trial Profile

NGR013: Phase I and Pharmacodynamic Study of NGR-hTNF Administered at High Doses in Patients With Advanced or Metastatic Solid Tumour.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs NGR-TNF (Primary)
  • Indications Colorectal cancer; Gastric cancer; Liver cancer; Mesothelioma; Neuroendocrine tumours; Non-small cell lung cancer; Pancreatic cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors MolMed
  • Most Recent Events

    • 08 Oct 2015 Planned End Date changed from 1 Dec 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov.
    • 08 Oct 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov.
    • 05 Apr 2015 Planned End Date changed from 1 Jun 2013 to 1 Dec 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top